Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 8/20 | 0.54 |
| ▸ | FNTB | P49356 | 8/20 | 0.54 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7563110 | 0.98 | FNTA (0.57) | FNTAFNTBPGGT1BTDP1 | |
| SCHEMBL7564790 | 0.91 | FNTA (0.49) | FNTAFNTBPGGT1B | |
| SCHEMBL8224926 | 0.90 | FNTA (0.43) | FNTAFNTBPGGT1B | |
| SCHEMBL7563915 | 0.89 | FNTA (0.51) | FNTAFNTBPGGT1B | |
| SCHEMBL7561963 | 0.88 | FNTA (0.54) | FNTAFNTBPGGT1B | |
| SCHEMBL7612446 | 0.87 | FNTA (0.53) | FNTAFNTBPGGT1B | |
| SCHEMBL7609223 | 0.86 | FNTA (0.52) | FNTAFNTBPGGT1B | |
| SCHEMBL7562658 | 0.86 | FNTA (0.41) | FNTAFNTBPGGT1B | |
| SCHEMBL7562986 | 0.85 | FNTA (0.43) | FNTAFNTBPGGT1BTDP1 | |
| SCHEMBL7563333 | 0.84 | FNTA (0.50) | FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020058665-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | ASTRAZENECA UK LIMITED | 2002-05-16 | — | — | US | disclosed |
| US-20020052376-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | ASTRAZENECA UK LIMITED | 2002-05-02 | — | — | US | disclosed |
| US-6342765-B1 | COMPOUNDS THAT INHIBIT FARNESYLATION OF MUTANT RAS GENE PRODUCTS; TREATING DISEASES, ESPECIALLY CANCER, WHICH ARE MEDIATED THROUGH FARNESYLATION OF RAS | ASTRAZENECA UK LIMITED (GB) | 2002-01-29 | — | — | US | disclosed |
| EP-1025088-B1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | ASTRAZENECA AB (SE) | 2001-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058665-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | FNTA, FNTB, RABGGTA | FNTA 1/4885FNTB 2/4885PGGT1B 39/4885 |
| US-20020052376-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | FNTA, FNTB, RABGGTA | FNTA 1/4885FNTB 2/4885PGGT1B 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.